Perspective Therapeutics reports 50% response rate in highest-dose cohort of VMT-α-NET trial

• Perspective Therapeutics announced interim Phase 1/2a results showing tumor responses and sustained disease control with VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors.
• Results are being presented at the ESMO Congress 2026 in Madrid, running October 23-27.
• No dose-limiting toxicities or adverse event-related treatment discontinuations were reported; some patients experienced severe side effects, including kidney events.
• Phase 3 site preparations are targeted for completion around year-end 2026, with trial initiation expected in 2027 following FDA alignment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231049PRIMZONEFULLFEED9852132) on October 23, 2026, and is solely responsible for the information contained therein.